“The existing condition has exposed some structural weaknesses inside the EU’s medicines source chain plus a superior dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides said. She advisable that provide chain issues be tackled in an EU pharmaceutical method anticipated